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Abstract
Background: Understanding the perceptions and attitudes of physicians is important. This knowledge assists in the
efforts to reduce the impact of their interactions with the pharmaceutical industry on clinical practice. It appears
that most studies on such perceptions and attitudes have been conducted in high-income countries. The objective
was to systematically review the knowledge, beliefs and attitudes of physicians in low and middle-income countries
regarding interactions with pharmaceutical companies.
Methods: Eligible studies addressed any type of interaction between physicians and pharmaceutical companies.
The outcomes of interest included knowledge, beliefs and attitudes of practicing physicians. The search strategy
covered MEDLINE and EMBASE databases. Two reviewers completed in duplicate and independently study
selection, data abstraction, and assessment of methodological features. The data synthesis consisted of a narrative
summary of the findings stratified by knowledge, beliefs and attitudes.
Results: We included ten reports from nine eligible studies, each of which had a number of methodological
limitations. Four studies found that the top perceived benefits of this interaction were receiving information and
rewards. In five out of eight studies assessing the perception regarding the impact of the interaction on the
behavior of physician prescription, the majority of participants believed it to be minor. In one of these studies,
participants perceived that impact to be lesser when asked about their own behavior. The attitudes of physicians
towards information and rewards provided by pharmaceutical company representatives (PCRs) (assessed in 5 and 2
studies respectively) varied across studies. In the only study assessing their attitudes towards pharmaceutical-
sponsored Continuing Medical Education, physicians considered local conferences to have higher impact. Their
attitudes towards developing policies restricting physicians’ interactions with PCRs were positive in two studies. In
one study, the majority of participants did not mind the public knowing that physicians were receiving gifts and
awards from drug companies.
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Conclusions: This review identified few studies conducted in low and middle-income countries. While physicians
generally perceived the impact of interactions on their behavior to be minor, their attitudes toward receiving
information and rewards varied across studies.
Keywords: Knowledge, Beliefs, Attitudes, Physicians, Pharmaceutical company representatives
Background
The appropriateness of marketing relationships between
physicians and the pharmaceutical industry has been de-
bated since the 1960s [1]. In 2012, the total expenditure
on drug promotion exceeded $28 billion in the US alone,
$20 billion in five European countries (UK, France,
Germany, Spain, Italy), and $26 billion in Japan [2].
Campbell et al. found that 84 % of doctors in the
United States reported some form of relationship with
the pharmaceutical or medical device industries in 2009
[3]. Also, pharmaceutical and medical device industries
found up to 60 % of accredited continuing medical edu-
cation costs in the US [4]. These types of interactions
appear to be more prevalent in certain low and middle-
income countries. A 2012 study in Libya reported that
94 % physicians in public and private practice received
at least one visit in the preceding year [5]. Another study
in Izmir Turkey found that pharmaceutical company
representatives visited 90 % of physicians at least once
per week [6].
A number of studies have found that pharmaceutical
drug promotions can influence demand for prescription
drugs [7], and physician visits for conditions treated by
heavily advertised drugs [8]. More specifically, there is
evidence of an association between exposure to the infor-
mation provided by pharmaceutical company representa-
tives (PCRs) and a greater frequency of prescribing [9].
In spite of the above evidence, most doctors believe that
that their interaction with the pharmaceutical industry does
not influence their prescription behavior [10]. A number of
studies found that, while doctors may acknowledge that
such interaction may influence others, they believe it does
not influence them personally [11, 12].
Physician’s perceptions and attitudes might hinder
efforts to reduce the impact of the pharmaceutical industry
on clinical practice. As a result, it would be important to
synthesize the evidence on the knowledge, beliefs and atti-
tudes of physicians. There are a number of factors related
to the level of country income that might affect the
perceptions and attitudes of physicians. One of those
factors is the existence of tighter regulatory control in
high-income countries. For example, in the States, the
Sunshine act requires drug and device manufacturers
to report payments and items of value given to physicians.
The existence of such regulations may increase physicians’
awareness but also affect their attitude towards accepting
payments and items of value. Also, it appears that most
studies of physicians’ perceptions and attitudes have been
conducted in high-income countries. Therefore, our object-
ive was to systematically review the knowledge, beliefs and
attitudes of physicians in low and middle-income countries
regarding interactions with pharmaceutical companies.
Methods
Eligibility criteria
The inclusion criteria were:
 Type of study design: quantitative design (e.g.,
survey study) and qualitative design (e.g., focus
group, interviews, semi-structured interviews);
 Types of participants: physicians practicing in low
or middle-income countries (LMIC). We used the
World Bank income classification of countries’
income level;
 Types of interactions: any form of interaction
between physicians and pharmaceutical companies
or PCRs (e.g., gifts, meeting with representatives of
drug companies or medical/surgical device
manufacturers; receiving free drug samples,
industry-provided meals; pharmaceutical-funded
research; pharmaceutical-sponsored continuous
medical education including travel funding;
consultancy; stock ownership);
 Types of outcomes: for the purpose of this study,
we used the following classification [13]:
◦ Knowledge (e.g., related to the extent of the
interaction between physicians and
pharmaceutical companies);
◦ Beliefs: (e.g., perceptions of the effect of the
interaction on quality of patient care);
◦ Attitude: (e.g., toward the appropriateness and
acceptability of the interaction).
We excluded studies that focus only on residents,
patients or general public and studies not published in
English.
Search strategy
A medical librarian assisted with designing the search
strategy (Additional file 1). We electronically searched in
September 2015 the MEDLINE and EMBASE databases
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using the OVID interface. The search strategy combined
terms for ‘physicians’ and ‘pharmaceuticals’, and used
free text words and medical subject heading. No search
filter was used. In addition, we reviewed the reference
lists of included studies and searched the grey literature
(theses and dissertations).
Selection of studies
Teams of two reviewers screened in duplicate and inde-
pendently titles and abstracts of identified citations for
potential eligibility. We obtained the full texts of citations
judged as potentially eligible by at least one of the two
reviewers. Then, the teams of two reviewers screened
in duplicate and independently the full texts for eligibility.
The reviewers resolved disagreements by discussion or with
the help of a third reviewer. We conducted calibration exer-
cises and used a standardized and pilot tested screening
form. We calculated the kappa statistic of agreement
between the reviewers.
Data collection
Teams of two reviewers used a standardized and pilot
tested screening form with detailed written instructions
to abstract data from eligible studies. Disagreements were
resolved by discussion or with the help of a third reviewer.
Abstracted data included the: study design, funding source,
characteristics and setting of the participants, type of inter-
action addressed, and results.
Assessment of methodological features of included
studies
Teams of two reviewers assessed in duplicate the meth-
odological features of each eligible study. They resolved
disagreements by discussion or with the help of a third
reviewer. The Criteria assessed were: sample size calcula-
tion, reporting of a sampling frame, the sampling method,
the response rate, and the validity of tool.
Data analysis and synthesis
We assessed the agreement between reviewers for full
text screening by calculating the kappa statistic. We did
not conduct a meta-analysis due to the nature of the
data. Instead, we narratively summarized findings strati-
fied by knowledge, beliefs and attitudes.
Results
Results of the search
Figure 1 shows the study flow. Of 11,189 citations cap-
tured by the search strategy, we identified ten reports of
nine eligible studies. One of the studies described both
quantitative and qualitative data in two separate reports
[14, 15]. The kappa statistic for full-text screening was
high at 0.893.
Table 1 describes the characteristics of the partici-
pants, setting, and type of interaction addressed in each
of these studies. The studies were conducted in six dif-
ferent countries: Yemen [14, 15], Libya [16], Turkey,
Nigeria [17], India [18] and Pakistan [19], Malaysia [20],
Iraq [21] and Brazil [22].
The specialties of physicians included were: both general
practitioners and specialists in five studies [18–20, 22];
specialists only in one study [21] physicians from private
and public hospitals in three studies [14–16, 20]; and not
specified in one study [17]. The types of interaction
assessed were: “visits by PCRs” in three studies [14, 15,
22]; “PCR marketing activity” (promotional tools such as
gifts or sponsorships) in four studies [16, 19, 22]; “PCR as
source of drug information” in four studies [14, 15, 17, 18,
21] and pharmaceutical-sponsored continual medical edu-
cation (CME) [20] and invitations to take part in CME
courses [22].
Methodological features
Table 1 also describes the methodological features of the
included studies. There were a number of methodological
limitations: only one study reported sample size calcula-
tion [22]; one study used random approach to sampling
and another used stratified random sampling [22] and
both described their sampling frame [22]; and response
rates across studies varied between 19.5 and 100 %.
Findings
Table 1 describes the findings of each study. The findings
addressed beliefs (measured as perceptions) and attitudes
but did not address knowledge. Below, we narratively
summarize these findings organized by the following topics:
1. Perceived benefits of the interaction (n = 4 studies);
2. Perceived impact of the interaction (n = 8 studies);
3. Attitudes towards information provided by PCRs
(n = 5 studies);
4. Attitudes towards rewards provided by PCRs
(n = 2 studies);
5. Attitudes towards policies that regulate the
interaction (n = 2 studies);
6. Attitudes towards public knowledge of the
interaction (n = 1 study);
7. Attitudes towards pharmaceutical-sponsored CME
(n = 1 study)
1. Perceived benefits of the interaction (n = 4 studies):
In one study, the percentages of participants who
agreed with the following as benefits from
interactions with PCRs were receiving: new
information about products (95 %), invitations to
conferences (35 %) and gifts (22 %) [16].
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In another study, physicians’ expectations about
promotional programs from drug companies
included: reliable educational publications (82 %);
medical equipment (57 %); free drug samples (54 %);
financial support for training courses (43 %); social
events (e.g., dinners, trips) (34 %); and gifts up to
$50 for private use (27 %). In a third study, the
majority of participants (82 %) were in favor of the
statement “detailing of a PCR increases my awareness”
[17]. In the study reporting qualitative data,
physicians considered the medical representatives
as “information providers”. They also reported
“beneficial patronage” and “financial support” as
reasons to accept their visits [14].
2. Perceived impact of the relationship (n = 8 studies):
In one of the studies, the effect of gifts on prescriptions
was perceived as high (18 %), medium (12 %), low
(44 %); and no effect (27 %). In the same study, 54 % of
the participants approved that doctors who receive
expensive advertising gifts tend to prescribe that
company’s products. Another study found that the
effect of the promotional tools of PCRs on the
prescribing practices of physicians in general was
perceived as minor by 62 % of the participants and
major by 38 %. Its impact on one’s own prescribing
practices (as opposed to ‘in general’) was perceived as
minor by 80 % and major by 20 % [16]. In the same
study, 42 % disagreed that pharmaceutical promotional
activity decreased rational drug prescribing, 32 %
agreed, and 27 % were neutral [16].
In the study reporting qualitative data, participants
accused the PCRs of creating problems, harming the
ethical reputation of the profession and, harming the
patients’ welfare. At the same time, most physicians
thought they were “immune” from being influenced
by their interactions with PCRs [14].
Another study found that the majority of its
participants (60 %) were in favor of the statement
Fig. 1 The study flow
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Table 1 Characteristics and methodological features of the included studies
Study ID
Study design






Study 1 & 2
• Physicians from
private and public




• Relationship with PCR
• Frequency of PCR visits
• PCR marketing activity
Study 2
• Interaction between PCRs
and physicians
• Physicians’ attitudes toward
these interactions and
the PCRs
• Reasons for accepting the
PCRs’ visits
• Sample size calculation
(both studies): not reported
• Sampling frame (both
studies): bot reported
• Sampling method (both
studies): purposeful sampling
• Response rate (both studies):
100 %
Both studies
• Interview guide developed
through a literature review,
then pilot tested with 3
physicians
Study 1
• Percentage of participants
reporting the following as
important factors in prescribing a
specific drug: relationship with
PCR (9 %), frequency of PCR visits
(34 %), PCR marketing activity
(13 %).
Study 2
• Most physicians thought they
were immune from being
influenced by their interactions
with PCRs.
• Physicians accept a PCR’s visit
because of the beneficial
patronage or the financial support
provided by the PCRs.
• Physicians recognize the
professional authority of PCRs as
information providers.
• Physicians considered accepting
the PCR’s visit was their moral duty.
• Participants still doubt the role of
representatives, with some accusing
them of creating problems, harming
the ethical reputation of the profession




• Doctors from selected
public and private
practice settings (N = 608)
• Libya
• August-October 2010
• Gifts received from PCRs
(e.g., printed materials,
simple gifts or drug
samples
• Sample size calculation:
not reported




• Response rate: 61 %
• Questionnaire developed
based on previous published
studies
• Perceived benefits from
interactions with PCRs: receiving
new information about products
(95 % approved), invitations to
conferences (35 % approved) and
receipt of gifts (22 % approved).
Attitudes towards accepting PCR
gifts: 25 % totally disapproved;
25 % clearly approved; 50 %
would accept gifts in some cases.
• Acceptance of gifts according to
educational value: of respondents
who did not disapprove of gift
provision, 82 % considered
educational gifts as appropriate;
49 % considered non-educational
gifts as appropriate. Belief that
pharmaceutical promotional activity
decreased rational drug prescribing:
42 % disagreed; 32 % agreed; and













Table 1 Characteristics and methodological features of the included studies (Continued)
• Perceived impact of pharmaceutical
promotion on prescribing decisions
of physicians: minor (62 %); major
(38 %). Perceived impact of
pharmaceutical promotion on own
prescribing decisions: minor (80 %);
major (20 %). Perceived need to
develop national policies to restrict
PCR interactions with doctors: 57 %.
• Awareness of guidelines regarding




• Specialists and general
practitioners in
government posts
(N = 446: 24 % GPs,
42 % specialists and
35 % residents)
• Turkey
• Visits by PCR (frequency,
duration)
• Promotional Program
• Provision of drug
information
• Sample size calculation:
not reported
• Sampling frame: list of
physicians from the Ministry
of Health and from the 1992
Izmir telephone directory
• Sampling method: stratified
random sampling
• Response rate: 91 %
• Questionnaire pretested
with 25 subjects
• Physicians’ expectations about
promotional programs: reliable
educational publications (82 %);
medical equipment (57 %); free
drug samples (54 %); financial
support for training courses (43 %);
social events (e.g., dinners, trips)
(34 %); and gifts of up to $50 for
private use (27 %).
• Support for the prohibition of
PCR visits to physicians: 54 %
• Attitudes towards promotional
programs: not ethical (33 %); not
ethical in some aspects (36 %);
ethical (20 %).
• Perceived effect of advertising
gifts on prescriptions: high (18 %);
medium (12 %); low (44 %); no
effect (27 %)
• 68 % thought the information
was unreliable.
• 94 % pointed out the necessity
for a reliable source of information
other than drug companies.
• 54 % approved that doctors who
receive expensive advertising gifts
tend to prescribe that company’s
products
• Public knowledge that physicians
were receiving gifts and awards
from drug companies did not











• Sample size calculation:
not reported




• Self-developed tool: content
first approved by the
Committee of The Penang
Medical Practitioners’ Society,
reviewed by 5 clinicians
in active medical service to
• Rated impact on clinical practice
by descending order, as it relates





















• Response rate: 19.5 %
ensure clarity and
appropriateness
• Pilot testing not reported
pharmaceutical firms and overseas
conferences
• Rated impact on clinical practice
by descending order, as it relates
to pharmaceutical firms: reputation











• March to October 2013
• Quality of promotional
information that is given by
MRs to physicians
• Sample size calculation:
not reported
• Sampling frame: not
reported
• Sampling method: not
reported
• Response rate: 63 %
• Self-developed tool; validation
not reported. Pilot testing not
reported
• Information from PCRs about
drug indication was perceived as
good and information about drug
contraindications and side effects
was perceived as weak.
• Academic physicians have a
significantly more negative opinion
than hospital physicians regarding
PCRs information on drug
contraindication
• Only hospital physicians found





• Doctors in University
College Hospital teaching
hospital (N = 163)
• Nigeria
• Provision of drug information • Sample size calculation:
not reported




• Response rate: 41 %
• Questionnaire developed




• Drug information was sourced
from colleagues (99 %), drug
reference books (97 %), PCRs
(93 %), materials from drug
companies (93 %), scientific
papers/journals/internet (91 %),
and drug promotion forum/product
launches (88 %).
• Perception of importance of PCR
as drug information source: efficient
(70 %), reliable and accurate (66 %),
influences prescription behavior
(72 %), useful and readily used
when prescribing (69 %)
• Perception of the effect of
detailing by a PCR of a promoted
drug: increases awareness (82 %),






and specialists from an
urban town (N = 57)
• India
• Provision of drug information • Sample size calculation:
not reported




• Response rate: 95 %
• Questionnaire based on
theoretical model, no
validation reported
• Perception that product
information provided by medical














Table 1 Characteristics and methodological features of the included studies (Continued)
Scheffer 2014 [22]
• Structured Interview
• Physicians in Sao Paolo,
Brazil (N = 300)




• Visits by sales promoters
and sales representatives
• Inexpensive objects for the
doctor’s office
• Invitations to take part in
continuing education courses
and events Scientific journals
sponsored by the laboratories
• Sample size calculation:
described in detail
• Sampling frame: Logistics
Control System (SICLOM)
of the STD, AIDS and Viral
Hepatitis Department of





• Response rate: not
reported
• Validation not reported;
pilot testing not reported
• Pharmaceutical companies’
actions were considered to have
a strong influence (10 %), slight
influence (50 %) or no influence








• Various districts of
Rawalpindi division,
Pakistan
• January –June 2010
• Sponsorships
• Scientific promotional tools
• Personal touch promotional tools
Common promotional tools.
• Sample size calculation:
not reported




• Response rate: 75 %
• Questionnaire was
adapted from existing one
• General practitioners perceived
common promotional gifts as
most effective tool for changing
the prescribing behavior; while
sponsorship and personal touch
promotional tools are considered
neutral and relatively least
important.
• Consultants perceived scientific
promotional tools as most
influencing in changing prescribing
behaviors in comparison with
other promotional tools; while













“detailing of a PCR increases my preference for
prescribing the promoted drug” [17].
The study conducted in Pakistan compared general
practitioners and consultants regarding their
perceptions of the sponsorships and three types of
promotional tools: “scientific”, “personal touch”, and
“common” (no further details were given). The tool
considered as the most effective for changing
prescribing behavior was “common promotional
gifts” for general practitioners, and “scientific
promotional tools” for consultants [19]. In another
study, the participants reported the following as
important factors in prescribing a specific drug:
relationship with PCR (9 %), frequency of PCR visits
(34 %), and PCR marketing activity (13 %) [15].
In a study assessing the impacts of CME on clinical
practice, physicians rated the reputation of the firm
as highest impact, followed by pharmaceutical
company representatives and advertisement or
sponsored announcement as lowest [20].
One study asked the physicians to rate the
influence of all actions of pharmaceutical
companies on their prescribing behavior and the
majority considered it of slight influence (50 %) or
no influence (40 %) [22].
3. Attitude towards information provided by PCRs
(n = 5 studies):
Five studies assessed the attitudes of physicians
towards the information provided by PCR. In the
first study, the importance of PCR as drug
information source differed between the
participants: efficient (70 %), reliable and accurate
(66 %), influences prescription behavior (72 %), and
useful and readily used when prescribing (69 %) [17].
In the second study, 68 % of the participants
thought that the information was unreliable, and
94 % pointed out the necessity for a reliable source
of information other than drug companies. In the
third study, product information provided by
medical representatives was perceived as biased and
insufficient (79 %) [18]. In the study reporting
qualitative data, physicians recognized the
professional authority of PCRs as information
providers [14]. In the fifth study, physicians in Iraq
considered that information provided by PCRs
concerning drug indication was good and that
concerning drug contraindication and side effects
was weak [21]. In this study, hospital physicians
found that information provided by PCRs were
useful while academic physicians did not [21]. The
difference between opinions of academic and
hospital physicians was significant concerning the
focus of PCRs on cost difference in their promoted
product [21].
4. Attitude towards rewards provided by PCRs
(n = 2 studies):
One study found that 25 % of participants totally
disapproved of receiving gifts, 25 % clearly approved,
and 50 % would accept gifts in some cases. Of those
who did not disapprove of gifts, 82 % considered
educational gifts appropriate and 49 % considered
non-educational gifts as appropriate [16]. One study
asked participants about how ethical it is to receive
promotional programs: 33 % found it ‘not ethical’,
36 % found it ‘not ethical in some aspects’, and 20 %
found it ‘ethical’.
5. Attitudes towards policies that regulate the
interaction (n = 2 studies):
Two studies discussed the perceptions and attitudes
towards policies that restrict the interactions of
physicians with PCRs. In the first study, 54 % of the
participants were in support of the restrictions. In
the second study, 57 % approved of developing such
policies [16]. That same study found that 99 % of
the participants had never read any guidelines
regarding PCR interactions [16].
6. Attitudes towards public knowledge of the
interaction (n = 1 study):
One study found that for 64 % of the participants,
public knowledge that physicians were receiving gifts
and awards from drug companies did not matter and
25 % reported they would mind and try to hide it.
7. Attitudes towards pharmaceutical-sponsored CME
(n = 1 study)
One study assessed the attitude of general practitioners
and specialists towards the pharmaceutical-sponsored
CME. This study found that local conferences were
considered to have a higher impact on clinical practices
than pharmaceutical talks, internet-based medical
education, conferences organized by pharmaceutical
firms and overseas conferences [20].
Discussion
Summary of findings
We identified nine studies assessing the knowledge, beliefs
and attitudes of physicians regarding interactions with
pharmaceutical companies, in low and middle-income
countries. The top reported perceived benefits of the inter-
action related to receiving new and reliable information.
Participants perceived that the impact of the relationship
on physicians’ prescription behavior was minor. They per-
ceived it to be lesser when asked about their own behavior.
Physicians’ attitudes towards information and towards
rewards provided by PCRs varied across studies. Their
attitudes towards developing policies restricting the
interaction of physicians with PCRs were positive. In one
study, the majority of participants did not mind the public
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knowing that physicians were receiving gifts and awards
from drug companies.
Strengths and limitations of the review
This is the first published systematic review about the
knowledge, beliefs and attitudes towards the interaction
of physicians in low and middle-income countries with
PCRs. Also, the last published systematic review on this
topic in high-income countries that we are aware of was
published in 2000 [10]. One limitation is that we only in-
cluded studies published in English. Other limitations
relate to shortcomings of the available primary studies:
none assessed knowledge, they used different, and mostly
non-validated questionnaires, and were conducted in
different settings with varying cultural and social
backgrounds.
Comparison to findings of similar reviews
We did not find other similar reviews conducted among
physicians in the region of our interest. A recently pub-
lished systematic review focusing on medical students,
from high-income countries and one middle-income
country, found variable attitudes towards pharmaceutical
marketing practices. The attitudes of students were
generally not in favor of restricting visits from PCRs or
sponsored educational presentations [23]. The older
systematic review published in 2000 conducted on both
physicians and residents in high income countries
found positive attitudes towards the information from
PCRs and that physicians approved that the interaction
affects their prescription behavior, more than residents
did [10] while our review found mixed attitudes. In the
absence of studies directly comparing attitude of physicians
in low and middle-income countries to those in high-
income countries, it is hard to infer how they compare.
Our findings suggest that, while physicians are aware
of the potential influence of the interaction with
pharmaceutical companies, they believe that they are
themselves less prone to that influence. A recently pub-
lished study found that the majority of doctors in
Germany believed that their prescribing habits were
not influenced by PCR visits [24]. Another study con-
ducted in Argentina found that half of the doctors believe
that the benefits from pharmaceutical industry influence
medical prescription. However, only 27 % believed that
such benefits influence their own prescriptions [25]. Such
beliefs, in addition to the perceived benefits of the inter-
action, likely contribute to some of the positive attitudes
towards information and rewards provided by PCRs.
Implications for policy makers
There is a need for policy interventions related to inter-
actions between physicians and PCRs to maximize their
potential benefits (e.g., receiving drug related information)
and minimize their potential harms (e.g. negative impact
on physicians’ prescription behavior) [26]. In order for
these interventions to be successful, they need to take into
account the knowledge, beliefs and attitudes of physicians.
Based on the findings of this review, such interventions
need to raise awareness amongst physicians about the evi-
dence that pharmaceutical drug promotion does affect
prescription behavior. The fact that the majority of physi-
cians are in favor for developing policies that restrict phy-
sicians’ interactions with PCRs suggests that such policies
would be acceptable and likely effective. As noted earlier,
such policies might be more challenging to introduce and
implement in low and middle-income countries compared
to high-income countries where these are already being
introduced (e.g. Sunshine act in the USA).
Implications for future research
Our findings show a significant gap in the published
research concerning our topic, particularly in low and
middle-income countries. Future studies should attempt
to directly compare the attitudes of physicians in low
and middle-income countries to those in high-income
countries. They should also explore how the healthcare,
political and economic structures affect those attitudes.
There is also a need to improve the quality of studies in
this field, particularly in terms of using validated survey
tools. Moreover, a systematic review assessing the know-
ledge, beliefs and attitudes of patients and the public can
assist in planning and implementing policy interventions.
Conclusions
We identified few studies conducted in low and middle-
income countries, each of which had a number of meth-
odological limitations. The top perceived benefits of the
interaction between physicians and pharmaceutical com-
panies were receiving information and rewards. While
physicians generally perceived the impact of interactions
on their behavior to be minor, their attitudes toward re-
ceiving information and rewards varied across studies.
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